Bio-Thera Solutions' Announcement on the Approval of Avzivi (Bavencio Injection) by the European Commission
Bio-Thera Solutions,: Bio-Thera Solutions voluntary disclosure announcement for its 1H 2024 performance forecast.
Bio-Thera Solutions voluntary disclosure announcement for its 1H 2024 performance forecast.
Bio-Thera Solutions voluntarily disclosed the announcement about milestone payment received for the authorization and commercialization agreement signed with Hikma Pharmaceuticals USA Inc. regarding BAT2206 (ustekinumab injection).
Bio-Thera Solutions voluntarily disclosed the announcement about the acceptance of the application for the marketing authorization of BAT2206 (Ustekinumab Injection) by the US FDA and the European Medicines Agency (EMA).
Bio-Thera Solutions Investor Event Record (July 18, 2024)
Bio-Thera Solutions Investor Event Record (July 4, 2024)
Bio-Thera Solutions voluntarily announced the progress of receiving the first payment for the BAT2506 (Golimumab injection) licensing and commercialization agreement with STADA.
Bio-Thera Solutions Announcement on the pharmaceutical registration certificate of citrate-conjugated belimumab injection (Betanin).
Bio-Thera Solutions' announcement regarding the approval of TOFIDENCE (toripalimab injection) by the European Commission.
Bio-Thera Solutions' Announcement Regarding Government Grants.
Bio-Thera Solutions announces shareholding reduction plan by shareholders who hold more than 5% of shares.
Bio-Thera Solutions voluntarily disclosed an announcement about the positive opinion of the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on AVZIVI (bevacizumab injection).
Biotech's announcement on signing a licensing and commercialization agreement with STADA for BAT2506 (golimumab) injection
Biotech voluntarily disclosed the announcement that BAT8008 combined with bevacizumab or combined BAT7104 obtained a notice of approval for drug clinical trials
Biotech voluntarily disclosed the announcement that BAT6005 and BAT1308 injections obtained approval letters for drug clinical trials
Biotech voluntarily disclosed the announcement that BAT1308 and BAT8006 obtained a notice of approval for drug clinical trials
Biotech's announcement on acceptance of the marketing license application for BAT2206 (usinumab) injection
Biotech 2024 First Quarter Report
Biotech voluntarily disclosed an announcement on TOFIDENCE (tocilizumab injection) receiving positive opinions from the European Medicines Agency's Human Medicines Committee
No Data